Search:
 

Accelerated Development and Introduction Plans (ADIPs)

The ADIPs programme aims to shorten the time lag between vaccines being proven safe and effective for use and their introduction in developing countries.

In the past, this delay has been decades long. For example, only 10% of infants in the world’s poorest countries had access to Hib and hepatitis B vaccines 15-18 years after certification.

GAVI has funded two ADIPs:

  • pneumoADIP
  • Rotavirus Vaccine Programme

pneumoADIP

Pneumococcal vaccine was licensed for use in the USA in 2000 and without the pneumoADIP, or the Pneumococcal Accelerated Development and Introduction Plan, might have taken up to 20 years to reach children in poorer parts of the world.

In 2007 it became supported by GAVI and is now approved for introduction in three GAVI countries.

Based at the Johns' Hopkins University Bloomberg School of Public Health, the pneumoADIP, has:

  • Gathered evidence to make the case for manufacturing vaccines for the developing world
  • Has increased the profile and understanding in countries about the severity of the pneumococcal disease and the need for immunisation. The data gathered has drawn the attention of regional, national and local health officials to the burden of disease and to the value of vaccination.

    Pneumococcus casues up to half of all cases of childhood pneumonia. Another major cause is Hib. Pneumonia is also a serious complication of measles. All three of these vaccines are available for GAVI-eligible countries and have the potential to save millions of lives.

Rotavirus Vaccine Program

The programme is a partnership of PATH, the US Centers for Disease Control and Prevention and WHO. With the help of the programme, rotavirus vaccine is now being made available to eligible countries within two years of licensing in industrialised markets.

GAVI's policies to accelerate access and availability of vaccines

include